Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.73 |
| ▸ | ESR1 | P03372 | 13/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.73 |
| ▸ | TOP1 | P11387 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469493 | 0.89 | HRAS (0.79) | HRASESR1ESR2TOP1POLB | |
| SCHEMBL14002809 | 0.87 | HRAS (0.69) | HRASESR1ESR2TOP1POLB | |
| SCHEMBL7510361 | 0.86 | HRAS (0.76) | HRASESR1ESR2TOP1POLB | |
| Hydrochloric Acid SCHEMBL6548715 | 0.85 | KDM4E (0.76) | HRASESR1ESR2TOP1POLB | |
| SCHEMBL29394871 | 0.85 | HRAS (0.78) | HRASESR1ESR2TOP1POLB | |
| Hydrochloric Acid SCHEMBL10688614 | 0.85 | KDM4E (0.76) | HRASESR1ESR2TOP1POLB | |
| Hydrochloric Acid SCHEMBL9124388 | 0.85 | KDM4E (0.76) | HRASESR1ESR2TOP1POLB | |
| SCHEMBL12348338 | 0.85 | TOP1 (0.70) | HRASESR1ESR2TOP1POLB | |
| SCHEMBL5889511 | 0.84 | HRAS (0.69) | HRASESR1ESR2TOP1POLB | |
| Stallimycin SCHEMBL108585 | 0.84 | HRAS (1.00) | HRASESR1ESR2TOP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068485-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068485-A1 | COMPOUNDS FOR USE AS BROMODOMAIN INHIBITORS | BRD1, BRDT, BRD4 | HRAS 276/4885ESR1 2899/4885ESR2 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.